evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

114 questions · 129 findings · 12 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 37 · 28.7%GRADE not reported 4 · 3.1%Very low 24 · 18.6%Low 37 · 28.7%Moderate 20 · 15.5%High 7 · 5.4%

Low‐molecular‐weight heparins or heparinoids vs unfractionated heparin

Death from all causes during treatment (range 6 days to 16 days) · acute ischaemic stroke

Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during treatment (range 6 days to 16 days) compared with unfractionated heparin (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins or heparinoids vs unfractionated heparin

Death from all causes during · acute ischaemic stroke

Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during compared with unfractionated heparin (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins or heparinoids vs unfractionated heparin

Deep vein thrombosis · acute ischaemic stroke

Low‐molecular‐weight heparins or heparinoids may leads to lower deep vein thrombosis during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins or heparinoids vs unfractionated heparin

Pulmonary embolism · acute ischaemic stroke

Low‐molecular‐weight heparins or heparinoids showed no clear difference in pulmonary embolism during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins or heparinoids vs unfractionated heparin

Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period (range 6 days to 16 days)⁹ · acute ischaemic stroke

Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Incidence of compromised microcirculation requiring invasive intervention (re‐exploration) (analysed by digit, · patients undergoing digital replantation after traumatic amputation

It is very uncertain whether low molecular weight heparin (LMWH) changes incidence of compromised microcirculation requiring invasive… compared with no LMWH (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Incidence of compromised microcirculation requiring invasive intervention (incision) (analysed by digit, · patients undergoing digital replantation after traumatic amputation

It is very uncertain whether low molecular weight heparin (LMWH) changes incidence of compromised microcirculation requiring invasive… compared with no LMWH (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Microvascular insufficiency due to vessel occlusion ‐ arterial occlusion (analysed by digit, · patients undergoing digital replantation after traumatic amputation

It is very uncertain whether low molecular weight heparin (LMWH) changes microvascular insufficiency due to vessel occlusion ‐ arterial… compared with no LMWH (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Microvascular insufficiency due to vessel occlusion ‐ venous occlusion (analysed by digit, · patients undergoing digital replantation after traumatic amputation

It is very uncertain whether low molecular weight heparin (LMWH) changes microvascular insufficiency due to vessel occlusion ‐ venous… compared with no LMWH (very low certainty).

1 finding from 1 review